Page Partners : GSK – Pills, Pay-To-Prescribe And The Disability File

By /
Page GSK disability file pills pay-to-prescribe

Page Outsourcing helped GSK recruit 62 professionals for a European headquarters relocation. That is the clean trophy. Behind it sits the older pharmacy cupboard: a $3bn US fraud settlement, pay-to-prescribe bribery controls, Zantac litigation, contaminated-drug manufacturing failures, and a UK disability judgment. Page did not write the prescriptions, misbrand the pills, or bury the safety data. Instead, it helped staff the machine and left the receipt sitting beside the medicine cabinet.

Page Staffs The Pill Machine

Page Outsourcing did not have to guess who GSK was. It said the name itself. On its Germany case-studies page, Page described GSK as a worldwide leader in pharmaceutical research, development and manufacturing. The job was not tiny either. GSK was relocating its European headquarters from Denmark and Southern Germany to Hamburg, and Page built a project team of five specialist consultants plus a project manager to recruit 62 professionals across Finance, IT, HR, Sales and Marketing.

That is not a stray CV in a drawer. It is recruitment support for a headquarters move. Finance. IT. HR. Sales. Marketing. The soft organs of a corporate body: money, systems, people, pitch and polish. Page did not simply help fill one chair. It helped feed the operational machine around one of the world’s biggest pharmaceutical names. Lovely. Another neat Page trophy. A case study with the fingerprints wiped off. Another client framed as a success story while the public record sits behind the glass, coughing into a handkerchief full of pills, invoices and old enforcement notices.

The $3 Billion Medicine Cabinet

The problem with GSK is not that TCAP has to dig for dirt. Instead, the problem is deciding which shelf of the pharmacy cupboard to open first.

In 2012, the US Department of Justice announced that GSK would plead guilty and pay $3bn to resolve criminal and civil liability arising from unlawful promotion of prescription drugs, failure to report certain safety data, and civil liability for alleged false price reporting. The DOJ called it the largest healthcare fraud settlement in US history at the time and the largest payment ever by a drug company.

The named drugs matter. Paxil. Wellbutrin. Avandia. These are not obscure little bottles hiding behind cough syrup. The DOJ said GSK agreed to plead guilty over misbranded Paxil and Wellbutrin, and over failing to report safety data about Avandia to the FDA. The government alleged Paxil was unlawfully promoted for treating depression in under-18s, even though the FDA had never approved it for paediatric use. It also alleged that a misleading medical journal article misreported a clinical trial as showing efficacy in under-18 depression when the study had failed to demonstrate efficacy.

That is not a paperwork splinter. It is a pharmaceutical machine talking to doctors and patients through fogged glass, then paying billions when the glass finally cracked.

Paxil, Wellbutrin, Avandia

The Paxil allegations are especially grim because they sit in the zone where medicine, children, depression and corporate sales all meet in the same locked room. According to the DOJ, GSK sponsored dinner programmes, lunch programmes, spa programmes and similar activities to promote Paxil use in children and adolescents. It also said data from other failed studies had not been made available.

Then there was Wellbutrin. The DOJ alleged GSK promoted it for weight loss, sexual dysfunction, substance addictions and ADHD, among other off-label uses, although it was approved at the time only for major depressive disorder. Doctors, meetings, resorts, advisory boards, continuing medical education, the full upholstered theatre of pharmaceutical persuasion.

Avandia brought the safety-data stink. According to the DOJ, GSK failed between 2001 and 2007 to include certain safety data in reports to the FDA, including post-marketing studies and data from studies undertaken after European regulators raised concerns about cardiovascular safety. Later, the FDA added black-box warnings on congestive heart failure and myocardial infarction risk.

That is the pill machine Page chose to put near its trophy wall. Not because Page caused the conduct. It did not. However, Page wanted the clean version of the association: global pharma, headquarters move, specialist recruitment, 62 professionals, nice tidy case study. TCAP prefers the full label.

Pay-To-Prescribe

Then comes the phrase that sounds like it was written by a corruption chef with a marketing degree: pay-to-prescribe.

In 2016, the US Securities and Exchange Commission announced that GSK had agreed to pay $20m to settle FCPA charges involving its China-based subsidiaries. The SEC said those subsidiaries engaged in pay-to-prescribe schemes to increase sales, with money, gifts and other things of value transferred to healthcare professionals. It also said the schemes led to millions of dollars in increased sales of GSK pharmaceutical products to China’s state health institutions.

Even the SEC language has a pulse if you read it slowly enough. Money. Gifts. Healthcare professionals. State health institutions. Sales. Controls. Books. Records. The official version does not need TCAP garnish. The corporate body was not merely selling medicine. Its China-based subsidiaries were accused by the regulator of running schemes where the road to prescriptions had gifts, money and broken controls along it.

GSK consented to the SEC order without admitting or denying the findings. Fine. So put that in. Keep the file clean. Still, the $20m penalty and the pay-to-prescribe finding sit there, one more brown stain on the lab coat.

The Plant With Bad Pills

There is also the Puerto Rico manufacturing scandal. In 2010, GSK agreed to pay $750m to resolve criminal and civil liability over manufacturing deficiencies at its Cidra plant. The public reporting on that case described contaminated products, defective medicines, mixed-up strengths, whistleblower warnings and a factory that eventually closed.

The whistleblower, Cheryl Eckard, was a former GSK quality-control manager. Reporting at the time said she raised serious manufacturing concerns and later received a record whistleblower award after the settlement. The case involved drugs including Paxil, Avandia, Bactroban and others. Once again, the language around the story is the familiar corporate recipe: patient safety in the brochure, deficient product controls in the file.

That is what makes the Page angle so clean. Page did not need to know every historic cupboard. It still chose the brand glow. GSK made a fine recruitment trophy because global pharma always does. Big company. Technical roles. Headquarters relocation. Skilled hires. Clean surface. Serious money. Underneath, however, the old floorboards were already noisy.

Zantac And The Litigation Aftertaste

The more recent Zantac file adds another taste of litigation smoke. In 2024, GSK agreed a settlement worth up to $2.2bn to resolve most US state-court product-liability cases involving Zantac. The claimants alleged cancer links. GSK did not admit liability and has maintained there is no reliable evidence that ranitidine caused cancer.

That caveat matters. TCAP is not saying a court has found Zantac caused those cancers. The article does not need that. Instead, the public-pressure point is simpler: another enormous medicine dispute, another mass of claims, another settlement figure with more zeroes than most corporate consciences can safely carry, and another line in the GSK file Page will never mention while celebrating recruitment delivery.

The Page case study gives you “62 professionals”. By contrast, the public record gives you a pharmacy aisle full of enforcement history, product litigation and compliance scars.

One is the menu.

The other is the kitchen.

The Disability File

However, the title of this piece is not just about pills and bribery controls. It is also about disability, because GSK’s public employment record gives TCAP a direct bridge into Page’s own dirty comfort zone: disability managed through process until the process becomes the problem.

In Hartunian v GlaxoSmithKline Services Unlimited, the employment tribunal found that the claimant was unfairly dismissed. It also found that the dismissal was discrimination arising from disability under section 15 of the Equality Act 2010, and that GSK breached the duty to make reasonable adjustments in the specified respects that succeeded.

The detail matters because it cuts through the corporate inclusion perfume. This was not a vague grievance in the fog. A tribunal judgment says unfair dismissal. It says discrimination arising from disability. The same judgment says reasonable-adjustments breach. The public file has a disabled worker, a capability route, Change Control tasks, redeployment issues and a finding that GSK failed to take reasonable steps to deploy the claimant to other work.

That does not mean every disability claim against GSK succeeds. Some do not. Nor does it mean Page caused GSK’s employment conduct. It did not. Still, Page Partners does not need fake glue. The pattern is already sticky enough.

Corporate Inclusion Meets Corporate Capability

Every large employer has the same ritual. It talks about inclusion, wellbeing, values, employee support, diversity networks, reasonable adjustments and human-centred leadership. Then a disabled worker enters the slow machinery of capability, performance, redeployment, operational need and managerial suspicion, and the words suddenly become wallpaper.

That is why the Hartunian file belongs in this article. Not as the biggest GSK scandal, because the $3bn fraud settlement is obviously the larger crater. The disability file matters because it brings the subject back to Page’s own lane: recruitment, candidate management, health, work, process and what happens when a person does not fit the spreadsheet.

Page knows this territory. In the Cepac file, when my own disability-related recruitment complaint hit the system, Page’s disclosed material showed redactions, internal containment, legal concern, “don’t call him” energy and a file that came back looking like a blackout poem with another man’s material wandering through the wrong door. That is not GSK’s doing. It is Page’s own stink.

So when Page stands beside GSK and says “look at this recruitment support”, TCAP is entitled to ask a different question.

Support for what kind of machine?

The Case Study Never Says Fraud

No Page case study ever says the interesting part.

It does not say “we helped a pharma giant whose US fraud settlement became a benchmark for corporate punishment”. Nor does it say “we supported recruitment for a company whose China-based subsidiaries later sat in an SEC pay-to-prescribe order”. No Page brochure writes “our client’s public history includes product-safety disputes, manufacturing failures, disability findings and litigation baggage heavy enough to need its own trolley”.

Instead, the reader gets the ritual phrases. Recruitment support. Headquarters relocation. Project team. Specialist consultants. Agile plan. Finance. IT. HR. Sales. Marketing. Sixty-two professionals. Clean words with clean shoes.

But that is exactly why Page Partners works. It takes the shiny Page receipt and asks what the receipt is attached to. The answer, in this case, is a pharmaceutical giant whose public record does not need TCAP to darken it. It came pre-blackened.

HR For The Pill Machine

The most interesting part of Page’s GSK case study is not just the headcount. It is the functions. Finance, IT, HR, Sales and Marketing.

That is the company nervous system. Finance counts the money. IT keeps the pipes working. HR manages the people. Sales and Marketing feed the market. These are not decorative roles. They are not peripheral. They keep the machine awake, clean, staffed, measured and profitable.

So when Page says it recruited into those areas, the image is not one lonely technician replacing a lightbulb. It is Page helping the headquarters apparatus breathe through a relocation. The back office. The people office. The sales mouth. The marketing polish. The sort of infrastructure that lets a global pharma giant talk about purpose while the public file remembers something less fragrant.

Again, Page did not create GSK’s scandal history. Nobody needs to pretend that. The sharper point is that Page platforms these clients when the lighting suits Page, then expects the public record to stay politely offstage. Bad luck. TCAP reads the programme notes.

The Old Pharmacy Smell

GSK will say it has changed. Large companies always do. Compliance improved. Controls were strengthened. Lessons were learned. New leadership arrived. Old practices were addressed. Reports were filed. Training happened. The PowerPoint got a fresh template.

Maybe some of that is true. Corporate reform can be real. But public memory is not obliged to delete the file because the company bought a new compliance carpet. The $3bn DOJ settlement remains part of the record. The SEC pay-to-prescribe order remains part of the record. The Zantac litigation settlement remains part of the record. Meanwhile, the Hartunian disability judgment remains part of the record.

That is what Page never seems to understand. A case study is not a private trophy. It is an invitation to inspect the room. Once Page says “look at our client work”, TCAP can say “fine, let’s look properly”.

And when you look properly, the GSK room does not smell of innovation alone. It smells of old pills, paid influence, safety data, manufacturing failures, litigation reserves and disability paperwork.

Page’s Favourite Defence Is Not Enough

The boring defence will be obvious. Page only recruited. Page was not involved in drug promotion. It did not run the China subsidiaries. The recruiter did not make Avandia safety reports. It did not dismiss the worker in Hartunian. Nobody is saying Page settled Zantac claims.

Correct.

However, that is also irrelevant to the Page Partners premise.

This series is not about pretending Page personally committed every client scandal. It is about Page’s judgement, Page’s trophy wall and Page’s eagerness to claim credit for staffing corporate machinery while leaving the ugly public file in another room. Page wants reputational benefit from its client associations. TCAP adds reputational cost.

That is the exchange.

If Page gets to publish the clean receipt, TCAP gets to publish the dirty context.

Pills, Pay-To-Prescribe And The Disability File

So here is the bill.

Page Outsourcing helped GSK recruit 62 professionals for a European headquarters relocation, including Finance, IT, HR, Sales and Marketing roles. The public GSK file includes a $3bn US healthcare fraud settlement, criminal pleas over Paxil, Wellbutrin and Avandia conduct, an SEC pay-to-prescribe FCPA order tied to China-based subsidiaries, a $2.2bn Zantac settlement with no admission of liability, manufacturing failures at Puerto Rico, and a UK disability judgment finding unfair dismissal, discrimination arising from disability and specified reasonable-adjustments breaches.

That is not a thin file.

Instead, it is a medicine cabinet with police tape on the handle.

Page saw a global pharma client and wrote the recruitment trophy. TCAP saw the same name and checked the warning label.

Sixty-two hires.

One pill machine.

A $3bn fraud settlement.

Pay-to-prescribe.

A disability file.

And Page, still standing there with the brochure, hoping nobody reads the side effects.

Unredacted.

Sources

Scroll to Top